Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Stopped Early completed to operational challenges and other strategic considerations, not for efficacy or safety reasons

Conditions

• Brain Edema
• Stroke, Acute

Interventions

• DRUG: BIIB093
• DRUG: Placebo

Sponsor

Remedy Pharmaceuticals, Inc.